Microdose Psychedelic Insights, the premier global guide to the business of psychedelics, hosted a successful Psychedelic Capital Conference in an entirely virtual format, Tuesday, July 26, 2022. The July edition of the Microdose event introduced the investors and attendees to top investors, entrepreneurs, psychedelic researchers, latest IPO and health leaders, sharing valuable insights into the psychedelic sector. Part of a bimonthly investor conference series that dives deep into psychedelic medicine investment, this event was focused on driving the psychedelic industry to the forefront of modern medicine. CEOs, capital advisors, analysts, and investment luminaries from across the global spectrum, shared valuable content about the growing psychedelic space, provided important report analysis, and discussed the latest news and market strategies. The July PsyCap featured segments on the introduction and potential of virtual reality (“VR”) to deal with mental health treatments in the psychedelic space. Capitalists, investors, financial institute heads, and other attendees, learned the latest financial updates about the market from an expert perspective, with a multi-disciplinary panel of experts including Jayashree Mitra, Nanea Ree Lyle Maxson, Agnieszka Sekula, Patrick Trucchio, and Maria Velkova, discussing how transformative technology is shaping the future of the industry and its impact on financial markets. “The psychedelics industry is poised to provide much-needed therapies to address various medical complications, including the surging mental health crisis. By bringing valuable insights directly to the people, we aim to democratize access to critical information and help average investors navigate this dynamic industry,” said Patrick Moher, President of Microdose Psychedelic Insights. Doing Good is a new segment that all Psychedelic Capital Conferences are featuring this year, as non-profits leveraged this global platform to showcase their important work. The July edition of PsyCap Doing Good presentation was hosted by Blessings Of The Forest’s Medical Reciprocity Manager, Dr. Kirran Ahmad. Blessing Of The Forest is a non-profit organization dedicated to advocating and preserving information about the medicinal plants and indigenous traditions of the Gabonese forest people. Along with several corporate presentations, the title sponsor for the July PsyCap event hosted their segment titled: Risk Management in Emerging Markets – Psychedelic Medicine and Therapies. Representatives of NFP, an international insurance broker and consulting company, offered panelists Scott Foster, Morgan Frick, and Adam Wilkins, who discussed how NFP came to this field. With NFP’s experience with other recent emerging markets, cannabis, in particular, it’s especially able to assist companies in this space. Mindstate Design Labs CEO Dillan DiNardo offered an understanding of the company’s mission to pharmacologically design therapeutic states of mind to be applied in medically supervised settings to heal mental health disorders. In addition, Microdose has created a public-facing Deal Board, powered by Mission Club, presenting an investment opportunity with Maya Health‘s CEO & Founder David Champion. Maya Health focuses on building a future where people have easy and safe access to psychedelic medicine. To learn more, please visit https://ibn.fm/dtpCF.

• Lidar provides high-precision 3D imaging that helps enable hands-free driving, autonomous vehicles, smart cities, robotics, and other smart infrastructure applications
• Cepton CEO Dr. Jun Pei, a pioneer who led the development of the revolutionary lidar during his tenure at Velodyne, was one of the first to focus on the ADAS market to bring lidar to the mass market
• Lidar is expected to be a $50B+ market by 2030 and Cepton’s technology will be in select General Motors cars starting next year
• Cepton recently grew its presence in Detroit with a new center of excellence and aims to expand active engagements and initiatives with automotive Tier 1s and OEMs

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is taking its patented Micro Motion Technology (“MMT(R)”) mainstream under the guidance of company CEO and lidar pioneer Dr. Jun Pei. “When Jun Pei decided to start Cepton five years ago, it was not a surprise to me that he wanted to build lidar in every single vehicle, to make every single driver on the road safer,” said Cepton Vice Chairman Dr. Winston Fu (https://ibn.fm/HVNnm). Dr. Pei is an optics and electronics entrepreneur and technologist with a Ph.D. in Electrical Engineering from Stanford University. He developed the first optical and acoustical combination technique in semiconductor thin film measurement and holds numerous patents in the field of metrology. Before co-founding Cepton, Dr. Pei established AEP Technology, which developed advanced 3D instruments and pioneered parallel computing in interference microscopy. Prior to his AEP tenure, he was an optics equipment senior scientist at KLA-Tencor and head of an engineering team at Velodyne Lidar where he advanced HDL-64 lidar. Lidar – a play on the words “light detection and ranging” – uses lasers to generate 3D images, and provides vital information including distance, speed, and dimensions. This enables accurate detection tracking of objects based on real-time data. Emerging lidar applications include Autonomous Vehicles (“AVs”), Advanced Driver Assistance Systems (“ADAS”), traffic and pedestrian monitoring in smart cities, security and facility management, crowd analytics, and various industrial applications. Cepton offers near-range to ultra-long-range lidar sensors, automotive software, and lidar perception solutions. The company’s patented Micro Motion Technology leverages a mirrorless, rotation-free, and frictionless 3D lidar imaging method, enhanced by proprietary micro-optical modules and integrated Custom Application-Specific Integrated Circuits (“ASICs”) to offer state-of-the-art illumination control and detection (https://ibn.fm/fSgWH). “Cepton is a fabricated word borrowing from the word perception,” said Dr. Pei in a company presentation video. “C-E-P-T is a part of perception and O-N is the ending of a Latin element, so Cepton really indicates it’s an element of perception. CPTN’s licensable technology enables seamless high-volume manufacturing in collaboration with the world’s leading OEMs, and the company aims to make its proprietary technology standard in vehicles. ”We thought ADAS in the near future would be the biggest market for lidar, and that’s why we focused all of our company efforts – whether it’s in technology invention or commercial development – into the ADAS industry,” said Dr. Pei in a recent interview with the Financial Times (https://ibn.fm/0ZNYr). As part of its strategy, Cepton recently opened a new center of excellence in Metro Detroit to expand active engagements and initiatives with original equipment manufacturers (“OEMs”). The company has a long-standing collaboration with Japan-based Tier 1 supplier Koito Manufacturing Co. Ltd. that led to them being awarded the largest ADAS lidar series production award from General Motors (https://ibn.fm/7XKvp). Cepton has rapidly advanced lidar research and innovation since its inception in 2016. With a dedicated team of researchers and scientists led by Dr. Jun Pei, the company aims to take its patented Micro Motion Technology mainstream, enabling scalable and intelligent 3D perception solutions across multiple major global markets. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• A recent Facts & Factors study reported that the global EV market is expected to pass $980 billion by 2028
• Mullen posted the strongest balance sheet in company history for the quarter ended June 30, 2022
• The company noted several key milestones in its journey to becoming a major presence in the EV world

If Mullen Automotive (NASDAQ: MULN) latest financial report is any indication, the double-digit growth projected for the electric vehicle (“EV”) industry is right on the money. The emerging electric vehicle manufacturer posted a record balance sheet for the quarter ended June 30, 2022 (https://ibn.fm/RmJq8). A recent Facts & Factors study noted that, according to the latest research study, global electric vehicle market size and share were valued at roughly USD $185 billion in 2021 and are expected to reach USD $980 billion by 2028 at a compound annual growth rate (“CAGR”) of 24.5% during the forecast period (2022–2028). The report analyzes various factors and their implications on the electric vehicle market’s growth (https://ibn.fm/dwT2e). The article further noted that “the electric vehicle was developed primarily to replace polluting traditional ways of transportation. As a result of various technological developments, it has gained in popularity. “[The electric vehicle] outperforms traditional automobiles in terms of fuel efficiency, carbon emissions and maintenance, as well as ease of charging at home, a smoother ride, and less engine noise,” the article continued. “Pure, hybrid and plug-in hybrid batteries are the three primary types of electric car batteries.” Mullen Automotive’s financial report for the latest quarter, which ended June 30, 2022, stated that the company has more than $61 million in cash and cash equivalents, after having significantly strengthened its balance sheet throughout the quarter. The company recently paid off a secured convertible promissory note executed in July 2020 with DBI Lease Buyback Servicing LLC, an affiliate of Drawbridge Investments LLC. As part of this announcement, the company noted that an existing Mullen shareholder acquired the note and entered into an agreement with Mullen to extend its maturity date by two years. In addition, Mullen has reached an agreement to secure $275 million in additional funding for the company, pending approval by company shareholders. “We’ve made solid progress over the past quarter,” said Mullen CEO and chair David Michery. “The company’s balance sheet is the strongest it has ever been in our history.” Financial numbers aren’t the only highlight on Mullen’s report. The company has previously noted several key milestones in its journey to becoming a major presence in the EV world. In May, the company delivered its first EV van through a pilot program with a U.S. telecommunications provider. This van is currently being modified to fit the specs required by the customer in anticipation of a purchase order. Mullen was recently added to the U.S. small-cap Russell 2000(R) Index. Membership in this index, which remains in place for one year, is based on membership in the broad-market Russell 3000(R) Index. As part of membership, the stock is automatically added to the appropriate growth and value indexes. Mullen is a Southern California–based automotive company that owns and partners with key businesses working toward the goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States that fit perfectly into the American consumer’s life. For more information about the company, visit www.MullenUSA.com. NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

• The medical care needs of military personnel are once again in the spotlight following a political dust-up over service members’ exposure to environmental hazards at burn pits
• Another long-standing concern among service personnel is the treatment of concussive brain injuries
• Although no FDA-approved prescription drug currently exists for treating concussions, medical product developer Odyssey Health Inc. is testing a device-drug combination designed to stop concussion injury in its tracks to avoid long-term harm
• Odyssey Health’s product would use an inhaler-like device to deliver the special medication into the nasal cavity for better uptake into the central nervous system, keying on its demonstrated ability to cross the blood-brain barrier

U.S. military service members’ healthcare concerns landed a new place in the spotlight during the past month when outraged veterans and veteran-friendly politicians called attention to a sudden reversal of fortune for a Congressional bill that promised expanded benefits to service members exposed to environmentally hazardous burn pits used in Iraq, Afghanistan, and elsewhere in the years after Sept. 11, 2001. The bill was slated to label 23 diseases as presumed to be linked to military service, which would have made it easier for veterans to receive expedited health services and disability compensation without having to prove their illness was service-related. But after initially garnering the votes it needed to pass, a required revote unexpectedly handed it a significant defeat that proponents blamed on political posturing (https://ibn.fm/qdgPl). Although the controversy’s passions pressured senators to reverse course again and grant the bill success as they’d originally intended, the bill’s proponents weren’t quick to forget the difficulties veterans sometimes face over access to healthcare (https://ibn.fm/7FQkj). Because of the novel nature of military service and tools, veterans’ medical concerns sometimes fall into the realm of unmet needs, whether because of political divisions or the simple lack of effective science to provide a treatment. Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY) has been advancing a proposed solution for another, more common medical concern afflicting veterans — brain injury from concussive forces. Odyssey Health’s novel compound PRV-002 is the combination of a device and the medicine it delivers to treat concussions during the first moments after their occurrence, before permanent or long-term damage can set in. No U.S. Food and Drug Administration (“FDA”)-approved drug treatment exists for concussions and medical providers are generally left to rely on prescribed rest to help patients recover, but if Odyssey’s product can be established as safe and effective it will open doors to first-of-its-kind responsiveness that may benefit not only service members, but athletes and ground-level fall victims as well. PRV-002 has already passed a series of tests in lab animal work and is currently being tested on human volunteers for safety, moving from a Single Ascending Dosing (“SAD”) stage to a Multiple Ascending Dosing (“MAD”) stage in which the volunteers will be treated once daily for five straight days. Once the safety testing is completed, Odyssey expects to launch into a Phase II testing designed to show its product is not only safe but demonstrably effective in treating concussed patients, using volunteer military service members for the trial. “We are actively identifying and assisting with Phase II military trial site setup,” Major General (Ret.) Jim Linder, the former chief of staff for the U.S. Special Operations Command, stated in a July 12 news release about the testing program (https://ibn.fm/PMC10). “We need a treatment to prevent the long-term consequences of concussion as far too many of our Service Members are retiring with TBI disorders that lessen their quality of life.” For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• • Esports industry maturing, attracting growing audience via star-studded tournaments, ticket sales, merchandise, live social media events
  • Industry expected to reach $12.5 billion at a CAGR of 21.9% by 2030
  • GMGI recently featured on Benzinga’s Esports Listmakers Series, CEO reveals upcoming launch of Esports platform
  • GMGI delivers easily customizable, configurable, modular solutions for B2B operators, recently achieved 15 consecutive profitable quarters
  The global Esports market is maturing into a multi-faceted entertainment enterprise, complete with tournaments, celebrities, and social media influencers. Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, aims to leverage this trend by adding an Esports platform to its growing portfolio of B2B iGaming and Esports solutions. A recent report by Research and Markets confirms the trend, projecting that the Esports market size will reach roughly $12.5 billion at a CAGR of 21.9% by 2030 (https://ibn.fm/cld8s). Increased mobile adoption, growth in emerging countries, and rising Esports awareness are just a few factors fuelling the trend. In addition, competitive leagues featuring athletes and celebrities are disrupting traditional sports media structures with established brands leveraging new marketing opportunities via sponsorships and advertising on social media platforms like Twitch and TikTok. Related industries are also emerging in ticket sales and merchandising to contribute substantially to overall industry growth. Golden Matrix, a leader in B2B iGaming and Esports solutions, was recently featured in financial media and data company Benzinga’s Esports Listmakers Series (https://ibn.fm/Cx75K). During the presentation, Golden Matrix CEO Brian Goodman revealed insights into the state of the industry, along with common challenges in running Esports tournaments online. “The only potential way to run gambling on Esports would be sanctioned events where it becomes a situation where the people that are playing would not want to throw a game do something because of their status,” said Goodman. “As a company, we put together a peer-to-peer Esports situation where people will be able to play each other and bet against each other, so obviously they wouldn’t be throwing their own match…we built this product and it has some soft games as well, and that’ll launch quite soon.” Golden Matrix boasts 15 consecutive profitable quarters – a testament to its successful B2B iGaming strategy (https://ibn.fm/X4dmY). The company offers highly modular, turnkey, and white label gaming platforms that can be easily customized by iGaming operators. With a focus on enhancing the customer experience, GMGI’s solutions are easy to use, and compatible with all major browsers, operating systems, and devices. GMGI simplifies iGaming and Esports operations with its portfolio that includes its GM-X Turnkey, GM-X White Label, and GM-X Direct Integration solutions. GM-X Turnkey is a complete software package that integrates thousands of games from leading content providers. GMGI’s GM-X White Label offering provides a complete solution with licensing, accounting, management, support, and gaming content. For operators requiring access to GMGI’s extensive gaming portfolio, the company’s GM-X Direct Integration offering provides a solution that acts as an integration layer between the operator and content provider on top of the GM-X aggregation system. Golden Matrix Group is the leading provider of turnkey and white label iGaming platforms, Esports technology, and gaming content. As the iGaming and Esports industries continue to grow, GMGI is favourably positioned to offer its B2B partners a distinct competitive advantage with flexible, highly modular, configurable, and scalable AI-powered gaming platforms that maximize their return on investment. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

• Eat Well’s goal of investing in the entire plant-based supply chain has seen it acquire Belle Pulses Ltd., Sapientia, and 51% of Amara Organic Foods
• It has also seen the company invest in the CPG sector, food technology, agribusiness, and the media sectors in what the management describes as a strong foundation within its investment platform
• The company recognizes the ongoing global supply chain challenges brought about by the COVID-19 pandemic, as well as the ongoing Russia-Ukraine war, as an opportunity to grow its market share and address an unfulfilled demand for its products
• It maintains its 2022 revenue projections for its portfolio companies at $100 million, attributing it to the strong foundation it has laid down so far, as well as the aggressive push for its brand in the market

Since its inception, Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) has remained committed to exploring and evaluating new investment opportunities in plant-based foods. Its operations have explored various sectors, including precision fermentation and regenerative agriculture, with the overall goal of investing in the entire plant-based supply chain in what it describes as a “seed-to-market” approach (https://ibn.fm/y1MGo). This outlook has seen Eat Well grow its portfolio significantly over the past few years, even securing awards for its pulse processing. In July 2021, the company completed a 100% acquisition of Belle Pulses Ltd., one of the top pulse processors in Canada, having exited 2020 with over $60 million in sales. The company would also close the acquisition of Sapientia and 51% ownership of Amara Organic Foods, with an option to increase it to 80%. Eat Well has made significant investments in the Consumer Packaged Goods (“CPG”) sector, food technology, agribusiness, and the media sectors, all of which serve to diversify its product and service offering, as well as its revenue earnings. Most of all, these investments have laid down a strong foundation for the company, an investment that is slowly paying off to the benefit of its shareholders. In June 2022, Eat Well released its financial results for the fourth quarter (“Q4”) and full year of 2021, noting a 1,082% asset growth from the previous year and a 320% revenue gain for Amara from 2020. The company also reported having raised $33.5 million of debt from a leading Canadian institution while also completing two subsequent event equity financings of $5.1 million and $5.018 million, respectively (https://ibn.fm/mtBui). While making the announcement, the company’s Director, President, and Chief Executive Officer (“CEO”) noted: “We have laid a strong foundation within the Eat Well Group investment platform, and we are very enthusiastic about the trajectory of our portfolio.” “The global plant-based foods market continues to rapidly expand as consumers make healthier decisions for themselves and their families. Our portfolio companies are well-positioned to capture global pulse demand and accelerate the scale of their better-for-you consumer products for years to come,” he added. With supply chain challenges brought about by the global COVID-19 pandemic, further exacerbated by the ongoing Russia-Ukraine war, consumers have had to deal with product shortages and subsequent price hikes. A United States Bureau of Labor Statistics report noted that food at home for the 12 months ended June 2022 had increased by 12.2%. In addition, food away from home (restaurants and fast food) increased by 7.7% in what the report described as “the largest 12-month increase since the period ending November 1981” (https://ibn.fm/TzHXS). While many might view this as a hurdle, Eat Well recognizes it as an opportunity. For instance, with the growing food security concerns, its subsidiary, Belle Pulses, is expanding its production facility in response. In addition, Mr. Aneed has also confidently stated that Amara Organic Foods is in an excellent position to deal with the shortages that have plagued the industry in the past few months to take advantage of the demand that is not being satisfied by the existing supply. Eat Well maintains its 2022 revenue projections for its portfolio companies at $100 million, and it is right on target given its annual financial statements released in June this year. The company attributes this to the strong foundation it has laid down so far and how aggressively it is pushing its brand in the market, not just by introducing new products but also by entering into distribution agreements with key retailers across North America. In addition, its subsidiaries are expanding their market reach and capacity in response to food security concerns arising from the war in Ukraine. For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

• CNS Pharmaceuticals is a U.S.-based drug innovator developing novel chemotherapy agents capable of taking the fight against cancerous tumors across the blood-brain barrier to directly attack cancerous growths of the central nervous system
• The company’s lead candidate is an anthracycline named Berubicin, which has previously shown promise among glioblastoma (“GBM”) patients in a safety study — particularly for one who remains cancer-free more than 15 years later
• CNS is enrolling patients in the United States, Italy, France, Spain, and Switzerland, for the global Phase 2 clinical trial to measure Berubicin’s potential to match or exceed the effectiveness of Lomustine, a standard-of-care chemotherapy agent used to treat GBM
• Berubicin has achieved fast track and orphan drug status from the FDA, opening priority regulatory pathways for the drug if it continues to demonstrate successes through the trial process

Glioblastoma (“GBM”) is a brain cancer that has no cure at the present time and few treatment options for patients. It is the most aggressive primary brain tumor, affecting approximately 13,000 newly diagnosed patients each year in the United States with an average survival time of less than a year after diagnosis. While the median age of diagnosis is 64 years and it is most common in men, recent news reports have drawn attention to its diagnosis in a 10-year-old Scottish girl (https://ibn.fm/Rn1lF) and a 39-year-old American teacher (https://ibn.fm/C8plY). CNS Pharmaceuticals (NASDAQ: CNSP) is working within a competitive worldwide field of biopharmaceuticals to develop a therapy for treating GBM. The company’s lead drug candidate is a novel anthracycline named Berubicin that has set itself apart from other potential therapies because of its apparent ability to cross the blood-brain barrier with central nervous system uptake. CNS Pharmaceuticals is conducting a potentially pivotal global Phase 2 clinical trial to measure Berubicin’s potential to match or exceed the effectiveness of Lomustine, a standard-of-care chemotherapy agent used in the treatment of GBM patients as the tumor progresses (https://ibn.fm/zNvGr). Patients are being enrolled at 19 sites thus far, with 42 more anticipated across the United States, Italy, France, Spain and Switzerland now that European regulatory approvals have been granted. The U.S. Food and Drug Administration (“FDA”) has granted “fast-track” and “orphan drug” status to Berubicin, demonstrating the value of CNS’s initial successes in opening regulatory pathways for the drug’s market priority if it can continue to show success in its trial stage. Berubicin generated excitement after its initial development by another company more than 15 years ago resulted in a positive finding among patients with recurrent primary brain tumors. The safety study ended with several patients demonstrating clinical benefits (a 44 percent rate) and one of them showing a cancer-free response and ongoing cancer-free survival up to the most recent evaluation during the current COVID pandemic (https://ibn.fm/ExK7y). It’s a difficult time for biopharmaceuticals — a severe market downturn amid inflationary pressures has challenged companies’ efforts to finance their operations. Walmart’s announcement that its profits would be affected (https://ibn.fm/wYpEw) was just one of the dark clouds appearing ahead of the latest move by the Federal Reserve in late July to use interest rates to combat inflation. Financial analysts at Evaluate Vantage e-magazine reported that out of the more than 600 drug developers they track with a market cap of $250 million or more, only a fifth ended June with their share prices up on the year (https://ibn.fm/NdSf8). CNS recently announced its own measures to maintain its financial strength amid the tough market pressures as stockholders met July 27 for their annual voting, and CEO John Climaco recorded a video message to personally explain the company’s strategy in regard to the potentially “controversial” vote to authorize a reverse stock split to be used as a tool if the board finds it necessary. “We simply cannot allow the company to be at the mercy of those market headwinds,” Climaco said in promoting the company’s market strategy (https://ibn.fm/hZy4y). “Our trial is going beautifully; the work of the last four years. We can see the interim analysis point just over the horizon next year. And we just feel as a board, and myself as the chairman, very passionately that we must have these tools in place to adapt to market conditions should they be needed.” CNS is also in the process of developing an anthracycline-based drug candidate labeled WP1244 that is believed to be 500 times more potent than chemotherapy agent daunorubicin in stopping tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity, according to the company. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

The upcoming Blockchain Futurist Conference, organized by Untraceable Events, is designed as a huge gamification experience. Untraceable Events has announced the launch of its token UNNY, which attendees can receive simply by participating in activities throughout the conference. In this system, gamification points are allotted to attendees when they complete tasks and find codes throughout the two days. These points are then converted to UNNY which can be used to redeem prizes at the conference. The more points an attendee accumulates, the higher they are ranked in the Futurist Conference Leaderboard in the event app. The conference will be running from August 9-10, 2022, unifying attendees, vendors, sponsors, and thought leaders of crypto, blockchain, NFTs, Metaverse, Defi, and Web3 world. The introduction of the token UNNY will encourage the attendees to actively participate in different experiences at the conference. The UNNY token will be launched in keeping with the main agenda of the conference, which is to boost the awareness and use of blockchain, cryptocurrency, and digital assets among local communities in Canada and throughout the world. This is how UNNY works:

• The main idea is to engage participants with different experiences at the conference. The more active participation, the more points you get.
• Actions that will gain points range from attending speaker sessions, visiting sponsor booths, posting on social media, or just finding codes throughout the venue.
• Untraceable Events have gamified previous Futurist Conferences by rewarding attendees with points, however this year they can convert those points into the UNNY tokens, built on the Polygon Network.
• Flexa will be used to accept the UNNY payments, and Earth Wallet is recommended to store your UNNY.  Representatives for both of these companies will be available for assistance at Blockchain Futurist Conference.
• Once you have participated in events and accumulated UNNY, you can visit the UNNY Booth at Futurist to redeem prizes, level up, and receive NFTs.

Founder Tracy Leparulo believes that this is the best way to make the most of the conference, encouraging attendees to participate in all the activities benefits everyone. It truly makes the event an immersive experience and allows attendees to enjoy the conference on a whole new level. Be a part of this mammoth event and discover some wonderful perks and offers that can be availed by using UNNY at Futurist Conference, including discounts on future events, Futurist NFTs, and more. To learn more about the conference, visit https://www.futuristconference.com. To learn more about the ETHToronto hackathon, visit https://www.ethtoronto.ca

• Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery system
• Results of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time point
• Ketamine typically used to induce and maintain anesthesia, drug use expanding to include depression and chronic pain treatment at subanesthetic doses

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, recently completed a study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership with Zylo Therapeutics (https://ibn.fm/BBCWC). Results of the small animal study produced positive endpoint results, demonstrating that Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points. Mechanical hyperalgesia was additionally reduced on day seven at the pre-dose time point. “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction,” said Eric Weisblum, CEO of Silo Pharma. “This data is extremely promising for patients suffering from fibromyalgia and rheumatoid arthritis. Additionally, I am delighted to report that day seven and day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.” Ketamine is typically used to induce and maintain anesthesia. The medication can produce a trance-like state that provides sedation, amnesia, and pain relief (https://ibn.fm/NT1z3). While some anesthetic agents often employed cause serious side effects (https://ibn.fm/Mot9g), ketamine anesthesia typically preserves airway reflexes and breathing while stimulating heart function and increasing blood pressure. Interest in ketamine has expanded beyond traditional uses to include treatment for depression (https://ibn.fm/8gWGf) and chronic pain (https://ibn.fm/iBhlg) at subanesthetic doses. The drug is on the World Health Organization’s List of Essential Medicines (https://ibn.fm/So2Wx) and has been referred to as a “major advance in the treatment of depression of the past 50 years” (https://ibn.fm/SpOCU). Silo Pharma aims to leverage the effects of ketamine via a patented administration method developed in partnership with Zylo Therapeutics Inc. called “Z-pod”. The company’s ketamine study aimed to demonstrate that Z-pod can hold and distribute ketamine and time-release the drug while diminishing potential hallucinogenic side effects. Besides ketamine, Z-pod is also being tested by Silo for other medicines, including psilocybin. Silo Pharma Inc. is dedicated to researching and developing innovative pharmaceutical solutions that help people suffering from indications such as chronic pain, rheumatoid arthritis, fibromyalgia, post-traumatic stress disorder (“PTSD”), Parkinson’s disease, Alzheimer’s disease, and other rare neurological disorders. The company identifies and partners with leading medical universities, providing financial resources that catalyze the progress of cutting-edge research through the clinical stage and into commercialization. For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• UUUU aggressively seeking to expand rare earth bearing monazite sand feeds
• Bahia Project offers potential to provide Energy Fuels with controlled, low-cost source of monazite
• Company plans extensive exploration work over the next several months to further define, quantify HMS and monazite resource at the Bahia Project

As an emerging player in the commercial rare earth business, Energy Fuels (NYSE American: UUUU) (TSX: EFR) has is strengthening its presence by entering into binding agreements to acquire 17 mineral concessions in Brazil (https://ibn.fm/o7vX5). The acquisitions, located in the state of Bahia and total approximately 58 square miles, have the potential to provide UUUU’s White Mesa Mill with large quantities of rare-earth-element and uranium-bearing natural monazite sand for decades. “This is another very significant step in Energy Fuels’ development as a major global rare earth element producer based in the United States,” said Energy Fuels CEO and president Mark Chalmers. “We are aggressively seeking to expand our monazite sand feeds. With guidance from our heavy mineral sand experts, the company has been evaluating the acquisition of monazite-bearing projects. “The Bahia deposit is well-known throughout the HMS (heavy mineral sand) industry as having excellent potential to produce high-quality ilmenite, rutile and zircon products, in addition to monazite,” Chalmers continued. “We are very pleased to have secured this project, as it has the potential to provide Energy Fuels with our own low-cost source of monazite feed that we fully control. “ Known as the Bahia Project, the mineral concessions that Energy Fuels is acquiring are located between the towns of Prado and Caravelas. Based on historical drilling results, the project holds significant quantities of heavy minerals, including monazite, titanium and zirconium. No previous mining has been done in the area, but extensive drilling has been performed and exploration and mining permits have been obtained for the concessions. Consequently, Energy Fuels anticipates a clear path to moving the Bahia Project to production. “The Bahia Project is a well-known heavy mineral sand (“HMS”) deposit with over 3,300 vertical historic exploration auger holes drilled to date, indicating significant concentrations of titanium (ilmenite and rutile), zirconium (zircon), and rare earth elements (monazite),” the company reported. “Importantly, the mineralization is at or near the surface, meaning the material is expected to be relatively easy to recover using standard, low-cost sand mining techniques.” Based on preliminary, historical resource estimates, Energy Fuels is confident that the Bahia Project could potentially provide its White Mesa Mill with anywhere from 3,000 to 10,000 tons per year of monazite sand concentrate; that production could last for decades. Energy Fuels plans to perform extensive exploration work over the next six months to further define and quantify the HMS resource at the Bahia Project. This work will likely include a comprehensive sonic drilling and geophysical mapping program to define the HMS grades and depths for the various mineral products. Energy Fuels anticipates supplementing its monazite supply in the future with open-market purchases, arrangements with existing monazite producers and/or additional acquisitions. The company is in advanced discussions with other current and future monazite producers around the world to provide creative options on how to best build upon existing momentum and add further scale. “In my view, this acquisition will provide significant credibility to investors, other monazite suppliers, and clean-energy manufacturers, as we will clearly demonstrate that Energy Fuels is well on its way to becoming a large-scale producer of advanced rare earth materials in the U.S.,” said Chalmers. “We have already proven our processing capabilities. Now we are proving that upon successful completion of this acquisition, we will own and control ‘the elements’ to supply EV, renewable energy and other technology manufacturers.” For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU